Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial
- PMID: 33091147
- DOI: 10.1111/eci.13424
Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial
Comment on
-
Colchicine in Patients with Chronic Coronary Disease.N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. N Engl J Med. 2020. PMID: 32865380 Clinical Trial.
Similar articles
-
Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2).Future Cardiol. 2021 May;17(3):411-414. doi: 10.2217/fca-2021-0027. Epub 2021 Mar 9. Future Cardiol. 2021. PMID: 33687270 No abstract available.
-
Colchicine in Patients with Chronic Coronary Disease.N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. N Engl J Med. 2020. PMID: 32865380 Clinical Trial.
-
[Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?].Ned Tijdschr Geneeskd. 2020 Oct 22;164:D4697. Ned Tijdschr Geneeskd. 2020. PMID: 33201620 Dutch.
-
Colchicine in the Management of Acute and Chronic Coronary Artery Disease.Curr Cardiol Rep. 2021 Jul 16;23(9):120. doi: 10.1007/s11886-021-01560-w. Curr Cardiol Rep. 2021. PMID: 34269908 Review.
-
Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?Am J Cardiovasc Drugs. 2021 Jan;21(1):1-10. doi: 10.1007/s40256-020-00408-y. Am J Cardiovasc Drugs. 2021. PMID: 32356107 Review.
Cited by
-
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323. Cancers (Basel). 2023. PMID: 37686599 Free PMC article. Review.
-
Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs.Arterioscler Thromb Vasc Biol. 2021 Aug;41(8):2237-2251. doi: 10.1161/ATVBAHA.121.316256. Epub 2021 Jun 10. Arterioscler Thromb Vasc Biol. 2021. PMID: 34107731 Free PMC article.
-
How to manage the abundant COVID-19 submissions to a peer-reviewed Scientific Journal.Eur J Clin Invest. 2021 Jun;51(6):e13569. doi: 10.1111/eci.13569. Epub 2021 Apr 13. Eur J Clin Invest. 2021. PMID: 33825197 Free PMC article. No abstract available.
-
Editorial: Implications of lipids and modified lipoproteins in atherogenesis: from mechanisms towards novel diagnostic and therapeutic targets.Front Cardiovasc Med. 2023 Jul 24;10:1245716. doi: 10.3389/fcvm.2023.1245716. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37554370 Free PMC article. No abstract available.
-
High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine.Front Cardiovasc Med. 2023 Oct 16;10:1264319. doi: 10.3389/fcvm.2023.1264319. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37908502 Free PMC article. Review.
References
REFERENCES
-
- Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology. London: John Churchill; 1858.
-
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
-
- Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752-762.
-
- Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782-1791.
-
- Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical